PL2444103T3 - Szczepionka przeciwko rakowi szyjki macicy - Google Patents

Szczepionka przeciwko rakowi szyjki macicy

Info

Publication number
PL2444103T3
PL2444103T3 PL09846240T PL09846240T PL2444103T3 PL 2444103 T3 PL2444103 T3 PL 2444103T3 PL 09846240 T PL09846240 T PL 09846240T PL 09846240 T PL09846240 T PL 09846240T PL 2444103 T3 PL2444103 T3 PL 2444103T3
Authority
PL
Poland
Prior art keywords
vaccine
cervical cancer
cervical
cancer
Prior art date
Application number
PL09846240T
Other languages
English (en)
Inventor
Hong-Jin Kim
Na Gyong Lee
Yang-Je Cho
Jin-Wook Jang
Hyoung Jin Kim
Kwang Sung Kim
Original Assignee
Eyegene Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43356558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2444103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eyegene Inc. filed Critical Eyegene Inc.
Publication of PL2444103T3 publication Critical patent/PL2444103T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL09846240T 2009-06-19 2009-10-20 Szczepionka przeciwko rakowi szyjki macicy PL2444103T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20090055179 2009-06-19
PCT/KR2009/006062 WO2010147268A1 (ko) 2009-06-19 2009-10-20 자궁경부암 백신
EP09846240.1A EP2444103B1 (en) 2009-06-19 2009-10-20 Vaccine for cervical cancer

Publications (1)

Publication Number Publication Date
PL2444103T3 true PL2444103T3 (pl) 2018-05-30

Family

ID=43356558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09846240T PL2444103T3 (pl) 2009-06-19 2009-10-20 Szczepionka przeciwko rakowi szyjki macicy

Country Status (11)

Country Link
US (1) US9566323B2 (pl)
EP (1) EP2444103B1 (pl)
JP (1) JP5758385B2 (pl)
KR (3) KR101181907B1 (pl)
CN (2) CN102215861B (pl)
AU (1) AU2009348078B2 (pl)
BR (1) BRPI0924981B1 (pl)
MX (1) MX2011013566A (pl)
PL (1) PL2444103T3 (pl)
TR (1) TR201802597T4 (pl)
WO (1) WO2010147268A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
MY184076A (en) * 2011-12-01 2021-03-17 Univ Cape Town Hpv chimaeric particle
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
WO2014046410A1 (ko) * 2012-09-20 2014-03-27 중앙대학교 산학협력단 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
KR20140060053A (ko) * 2012-11-09 2014-05-19 아이진 주식회사 인플루엔자 백신용 면역증강제
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
JP6663438B2 (ja) 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
WO2018080252A1 (ko) * 2016-10-31 2018-05-03 아이진 주식회사 면역반응 조절물질 및 이를 포함하는 백신 조성물
AU2017351900B2 (en) * 2016-10-31 2020-11-26 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233639T2 (de) 1991-07-19 2007-05-31 Csl Ltd., Parkville Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5888516A (en) 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
US6685949B1 (en) * 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR100423480B1 (ko) * 2001-11-20 2004-03-18 삼성전자주식회사 복수의 토너농도센서를 가지는 프린터 및 그의토너공급제어방법
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
SI1572233T1 (sl) * 2002-12-20 2011-07-29 Glaxosmithkline Biolog Sa Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
KR101361769B1 (ko) 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Hpv-16 l1 vlp 및 hpv-18 l1 vlp 백신
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
GB0323968D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
KR100740237B1 (ko) * 2005-05-10 2007-07-18 아이진 주식회사 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제
MX2007014390A (es) * 2005-05-19 2008-02-12 Glaxosmithkline Biolog Sa Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante.
CN101287489A (zh) * 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1986664A4 (en) * 2006-02-01 2009-07-22 Eyegene Inc COMPOSITION FOR THE TREATMENT OF CANCER WITH OLIGONUCLEOTIDES AND NON-TOXIC LPS

Also Published As

Publication number Publication date
KR20120083263A (ko) 2012-07-25
CN102215861B (zh) 2014-10-08
JP2012530488A (ja) 2012-12-06
BRPI0924981B1 (pt) 2022-02-08
KR20100136889A (ko) 2010-12-29
EP2444103A1 (en) 2012-04-25
CN102215861A (zh) 2011-10-12
WO2010147268A1 (ko) 2010-12-23
US9566323B2 (en) 2017-02-14
AU2009348078A1 (en) 2011-12-15
JP5758385B2 (ja) 2015-08-05
TR201802597T4 (tr) 2018-03-21
CN104288763B (zh) 2018-03-06
EP2444103B1 (en) 2017-12-20
CN104288763A (zh) 2015-01-21
EP2444103A4 (en) 2013-12-18
AU2009348078B2 (en) 2013-03-14
US20120100169A1 (en) 2012-04-26
BRPI0924981A2 (pt) 2016-03-15
KR101595779B1 (ko) 2016-02-19
KR20130083426A (ko) 2013-07-22
KR101181907B1 (ko) 2012-09-11
KR101345205B1 (ko) 2013-12-27
MX2011013566A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
ZA201109164B (en) Vaccine
GB0905570D0 (en) Combined vaccines
EP2519196A4 (en) WOMB-SPACER
ZA201204050B (en) Vaccination syringe
IL215764A0 (en) Adjuvant cancer therapy
GB201006165D0 (en) Vaccine
IL214257A0 (en) Peptides for vaccine
GB201003293D0 (en) Cancer vaccine
EP2346531A4 (en) ANTITUMOR VACCINE
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB201000522D0 (en) Vaccine
GB0910751D0 (en) Prostate cancer vaccine
ZA201201387B (en) Bovine herpesvirus vaccine
GB0921088D0 (en) Prostate Cancer DNA Vaccine
HRP20180744T1 (hr) Terapeutska cjepiva
GB201013006D0 (en) Vaccine
IL217194A0 (en) Vaccine
EP2416807A4 (en) NEW STRATEGIES FOR IMPROVED CANCER VACCINES
GB0914545D0 (en) Vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0909146D0 (en) Vaccines
GB0909147D0 (en) Vaccines
GB0909145D0 (en) Vaccines
GB0909144D0 (en) Vaccines